Question 1

What are the potential side effects of the new treatment compared to ADVAIR?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma clinical trial (NCT05664061). Contact the study team or your healthcare provider for specific answers.

Question 2

How will my asthma be monitored during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma clinical trial (NCT05664061). Contact the study team or your healthcare provider for specific answers.

Question 3

What happens if I experience an asthma exacerbation during the study?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma clinical trial (NCT05664061). Contact the study team or your healthcare provider for specific answers.

Question 4

How will this trial fit into my overall asthma management plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma clinical trial (NCT05664061). Contact the study team or your healthcare provider for specific answers.

Question 5

What are the logistics of attending the study visits, and how often will I need to come in?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Bioequivalence With Clinical Endpoint Study of Fluticasone Propionate 100 mcg and Salmeterol 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 100/50 mcg Inhalation Powder/GSK in Patients With Asthma clinical trial (NCT05664061). Contact the study team or your healthcare provider for specific answers.

What this study is about